Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Glomerulosclerosis Clinical Trials

A listing of Glomerulosclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (5) clinical trials

A clinical trial to evaluate treatments using Prednisone, Basiliximab, Mycophenolate Mofetil (MMF), Bleselumab, Tacrolimus Capsules, Methylprednisone for patients

The study will consist of the following periods: Screening (Days -21 to -1), Transplant (Day 0), Post-Transplant (Day 0/post-skin closure through 12 months post-transplant). All subjects will enter into a Screening Period (Days -21 to -1 prior to transplant), undergo a Transplant (Day 0 [zero]), and are then to be ...


A clinical research study for the treatment of Focal glomerulosclerosis, HIV-Associated Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) and a related condition, collapsing glomerulopathy, are chronic renal diseases affecting the glomerular podocytes. Currently, over thirteen genetic mutations are associated with FSGS. We are interested in expanding our understanding of these and other genes that may cause FSGS and collapsing glomerulopathy. We will study individuals ...

Phase N/A

Patients are needed to participate in a clinical research study of Diabetic Nephropathy to evaluate BI 685509, Placebo

The main objective of this trial is the safety and tolerability of 4 multiple rising oral doses of BI 685509 over 28 days in male and female patients with Diabetic Nephropathy (DN) as adjunctive to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB). Another objective is the change ...


A Phase 1 clinical study for patients using Eplerenone, BI 690517, Placebo

The primary objective of this current trial is to investigate the safety and tolerability of 5 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy as add-on-therapy to Angiotensin Converting Enzyme inhibitor [ACEi] or Angiotensin-receptor blockers [ARB]. Secondary objective is to evaluate the ...


A clinical trial to evaluate treatments for patients with NIDDM, Diabetic Nephropathy

The purpose of this protocol is to examine the effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin on kidney disease progression in American Indians with type 2 diabetes and early diabetic kidney disease (DKD) via a double-blinded placebo-controlled clinical trial. This trial will enroll 100 participants who will be ...